Single nucleotide polymorphisms in the toll-like receptor 3 and CD44 genes are associated with persistence of vaccine-induced immunity to the serogroup C meningococcal conjugate vaccine

Clinical and Vaccine Immunology

Volumn 19, Issue 3, 2012, Pages 295-303

  Moore, Catrin E ^a,b,c,g   Hennig, Branwen J ^d,e   Perrett, Kirsten P ^a,f   Hoe, J Claire ^a   Lee, Sue J ^b,c   Fletcher, Helen ^e   Brocklebank, Denise ^e   O'Connor, Daniel ^a   Snape, Matthew D ^a   Hall, Andrew J ^d   Segal, Shelley ^a   Hill, Adrian V S ^e   Pollarda, Andrew J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b MAHIDOL UNIVERSITY   (Thailand)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f UNIVERSITY OF MELBOURNE   (Australia)

^g Angkor Hospital for Children   (Cambodia)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; MENINGOCOCCUS VACCINE;

ADOLESCENT; ADULT; ANTIBODY TITER; ARTICLE; BACTERIAL GENE; CAUCASIAN; CD44 GENE; CHILD; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC ASSOCIATION; GENETIC IMMUNIZATION; GENETIC MARKER; GENETIC RISK; GENETIC VARIABILITY; GROUPS BY AGE; HUMAN; HUMAN EXPERIMENT; IMMUNE RESPONSE; IMMUNOGENICITY; IN VITRO STUDY; INFANT; INFECTION PREVENTION; INFECTION RISK; MALE; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; NORMAL HUMAN; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; SCHOOL CHILD; SERUM BACTERICIDAL ANTIBODY ASSAY; SINGLE NUCLEOTIDE POLYMORPHISM; TOLL LIKE RECEPTOR 3 GENE; TREATMENT DURATION;

ADOLESCENT; ANTIBODIES, BACTERIAL; ANTIGENS, CD44; BLOOD BACTERICIDAL ACTIVITY; CHILD; CHILD, PRESCHOOL; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; IMMUNOGLOBULIN G; INFANT; MALE; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; POLYMORPHISM, SINGLE NUCLEOTIDE; TIME FACTORS; TOLL-LIKE RECEPTOR 3; YOUNG ADULT;

EID: 84863298293     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.05379-11     Document Type: Article

References (29)

1. Ambrosino DM, et al. 1985. Correlation between G2m(n) immunoglobulin allotype and human antibody response and susceptibility to polysaccharide encapsulated bacteria. J. Clin. Invest. 75:1935-1942. (Pubitemid 15233581)
2. Borrow R, Andrews N, Goldblatt D, Miller E. 2001. Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection. Infect. Immun. 69:1568-1573. (Pubitemid 32187610)
3. Borrow R, Balmer P, Miller E. 2005. Meningococcal surrogates of protection-serum bactericidal antibody activity. Vaccine 23:2222-2227. (Pubitemid 40341456)
4. Campbell H, Borrow R, Salisbury D, Miller E. 2009. Meningococcal C conjugate vaccine: the experience in England and Wales. Vaccine 27(Suppl 2):B20-B29.
5. Dhiman N, et al. 2008. Associations between SNPs in Toll-like receptors and related intracellular signaling molecules and immune responses to measles vaccine: preliminary results. Vaccine 26:1731-1736.
6. Doulet N, et al. 2006. Neisseria meningitidis infection of human endothelial cells interferes with leukocyte transmigration by preventing the formation of endothelial docking structures. J. Cell Biol. 173:627-637. (Pubitemid 43765207)
7. Gabriel SB, et al. 2002. The structure of haplotype blocks in the human genome. Science 296:2225-2229. (Pubitemid 34680308)
8. Gheesling LL, et al. 1994. Multicenter comparison of Neisseria meningitidis serogroup C anti-capsular polysaccharide antibody levels measured by a standardized enzyme-linked immunosorbent assay. J. Clin. Microbiol. 32:1475-1482. (Pubitemid 24179378)
9. Goldschneider I, Gotschlich EC, Artenstein MS. 1969. Human immunity to the meningococcus. J. Exp. Med. 129:1307.
10. Granoff DM, et al. 1998. A modified enzyme-linked immunosorbent assay for measurement of antibody responses to meningococcal C polysaccharide that correlate with bactericidal responses. Clin. Diagn. Lab. Immunol. 5:479-485. (Pubitemid 28342873)
11. Hennig BJ, et al. 2008. Host genetic factors and vaccine-induced immunity to hepatitis B virus infection. PLoS One 3:e1898.
12. Kimman TG, Vandebriel RJ, Hoebee B. 2007. Genetic variation in the response to vaccination. Community Genet. 10:201-217. (Pubitemid 47482080)
13. Ladhani SN, et al. 2010. Association between single-nucleotide polymorphisms in Mal/TIRAP and interleukin-10 genes and susceptibility to invasive Haemophilus influenzae serotype b infection in immunized children. Clin. Infect. Dis. 51:761-767.
14. Majumder PP, et al. 2009. Genetic determinants of immune-response to a polysaccharide vaccine for typhoid. Hugo J. 3:17-30.
15. Newport MJ, et al. 2004. Genetic regulation of immune responses to vaccines in early life. Genes Immun. 5:122-129. (Pubitemid 38967641)
16. Ovsyannikova IG, et al. 2010. Rubella vaccine-induced cellular immunity: evidence of associations with polymorphisms in the Toll-like, vitamin A and D receptors, and innate immune response genes. Hum. Genet. 127:207-221.
17. Pandey JP, et al. 1979. Association between immunoglobulin allotypes and immune responses to Haemophilus influenzae and meningococcus polysaccharides. Lancet i:190-192.
18. Perneger TV. 1998. What's wrong with Bonferroni adjustments. BMJ 316:1236-1238. (Pubitemid 28171344)
19. Perrett KP, et al. 2010. Antibody persistence after serogroup C meningococcal conjugate immunization of United Kingdom primary-school children in 1999-2000 and response to a booster: a phase 4 clinical trial. Clin. Infect. Dis. 50:1601-1610.
20. Poland GA, Ovsyannikova IG, Jacobson RM, Smith DI. 2007. Heterogeneity in vaccine immune response: the role of immunogenetics and the emerging field of vaccinomics. Clin. Pharmacol. Ther. 82:653-664.
21. Pollard AJ, Perrett KP, Beverley PC. 2009. Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat. Rev. Immunol. 9:213-220.
22. Ramsay ME, Andrews NJ, Trotter CL, Kaczmarski EB, Miller E. 2003. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ 326:365-366. (Pubitemid 36241472)
23. Ryckman KK, et al. 2010. Host genetic factors and vaccine-induced immunity to HBV infection: haplotype analysis. PLoS One 5:e12273.
24. Schulz KF, Grimes DA. 2005. Multiplicity in randomised trials. I. Endpoints and treatments. Lancet 365:1591-1595. (Pubitemid 40615409)
25. Sirugo G, et al. 2008. Genetic studies of African populations: an overview on disease susceptibility and response to vaccines and therapeutics. Hum. Genet. 123:557-598.
26. Snape MD, et al. 2008. Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study. BMJ 336:1487-1491. (Pubitemid 351977021)
27. Snape MD, et al. 2008. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. JAMA 299:173-184.
28. Zarember KA, Godowski PJ. 2002. Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. J. Immunol. 168:554-561. (Pubitemid 34049553)
29. Zollinger WD, Mandrell RE. 1983. Importance of complement source in bactericidal activity of human antibody and murine monoclonal antibody to meningococcal group B polysaccharide. Infect. Immun. 40:257-264. (Pubitemid 13163064)